New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study

被引:15
作者
Cai, Qing-Qing [1 ,2 ]
Hu, Li-Yang [1 ,2 ]
Geng, Qi-Rong [1 ,3 ]
Chen, Jie [4 ,5 ]
Lu, Zhen-Hai [1 ,6 ]
Rao, Hui-Lan [1 ,7 ]
Liu, Qing [1 ,8 ]
Jiang, Wen-Qi [1 ,2 ]
Huang, Hui-Qiang [1 ,2 ]
Lin, Tong-Yu [1 ,2 ]
Xia, Zhong-Jun [1 ,3 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou 510060, Guangdong, Peoples R China
[4] Guangdong Prov Key Lab Arrhythmia & Electrophysio, Guangzhou 510120, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Radiotherapy, Guangzhou 510120, Guangdong, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Carcinoma, Guangzhou 510060, Guangdong, Peoples R China
[7] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China
[8] Sun Yat Sen Univ, Ctr Canc, Dept Canc Prevent Res, Guangzhou 510060, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Diffuse large B-cell lymphoma; Central nervous system relapse; Risk factor; Rituximab; Intrathecal chemotherapy prophylaxis; CHEMOTHERAPY PLUS RITUXIMAB; NON-HODGKINS-LYMPHOMA; ELDERLY-PATIENTS; CNS PROPHYLAXIS; CHOP CHEMOTHERAPY; R-CHOP; ERA; INVOLVEMENT; STRATEGIES; IMPACT;
D O I
10.1186/s40880-016-0150-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In patients with diffuse large B-cell lymphoma (DLBCL), central nervous system (CNS) relapse is uncommon but is nearly always fatal. This study aimed to determine the risk factors for CNS relapse in DLBCL patients and to evaluate the efficacy of rituximab and intrathecal chemotherapy prophylaxis for CNS relapse reduction. Methods: A total of 511 patients with newly diagnosed DLBCL treated at the Sun Yat-sen University Cancer Center between January 2003 and December 2012 were included in the study. Among these patients, 376 received R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as primary treatment, and 135 received CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) as primary treatment. Intrathecal chemotherapy prophylaxis (methotrexate plus cytarabine) was administered to those who were deemed at high risk for CNS relapse. In the entire cohort and in the R-CHOP set in particular, the Kaplan-Meier method coupled with the log-rank test was used for univariate analysis, and the Cox proportional hazards model was used for multivariate analysis. Differences were evaluated using a two-tailed test, and P < 0.05 was considered significant. Results: At a median follow-up of 46 months, 25 (4.9%) patients experienced CNS relapse. There was a trend of reduced occurrence of CNS relapse in patients treated with rituximab; the 3-year cumulative CNS relapse rates were 7.1% in CHOP group and 2.7% in R-CHOP group (P = 0.045). Intrathecal chemotherapy prophylaxis did not confer much benefit in terms of preventing CNS relapse. Bone involvement [hazard ratio (HR) = 4.21, 95% confidence interval (CI) 1.38-12.77], renal involvement (HR = 3.85, 95% CI 1.05-14.19), alkaline phosphatase (ALP) > 110 U/L (HR = 3.59, 95% CI 1.25-10.34), serum albumin (ALB) < 35 g/L (HR = 3.63, 95% CI 1.25-10.51), treatment with rituximab (HR = 0.34, 95% CI 0.12-0.96), and a time to complete remission = 108 days (HR = 0.22, 95% CI 0.06-0.78) were independent predictive factors for CNS relapse in the entire cohort. Bone involvement (HR = 4.44, 95% CI 1.08-18.35), bone marrow involvement (HR = 11.70, 95% CI 2.24-60.99), and renal involvement (HR = 10.83, 95% CI 2.27-51.65) were independent risk factors for CNS relapse in the R-CHOP set. Conclusions: In the present study, rituximab decreased the CNS relapse rate of DLBCL, whereas intrathecal chemotherapy prophylaxis alone was not sufficient for preventing CNS relapse. Serum levels of ALB and ALP, and the time to complete remission were new independent predictive factors for CNS relapse in the patients with DLBCL. In the patients received R-CHOP regimen, a trend of increased CNS relapse was found to be associated with extranodal lesions.
引用
收藏
页数:12
相关论文
共 31 条
[1]   Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516-The Southwest Oncology Group [J].
Bernstein, Steven H. ;
Unger, Joseph M. ;
LeBlanc, Michael ;
Friedberg, Jonathan ;
Miller, Thomas P. ;
Fisher, Richard I. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) :114-119
[2]   CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [J].
Boehme, Volkmar ;
Schmitz, Norbert ;
Zeynalova, Samira ;
Loeffler, Markus ;
Pfreundschuh, Michael .
BLOOD, 2009, 113 (17) :3896-3902
[3]   A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma [J].
Cheah, C. Y. ;
Herbert, K. E. ;
O'Rourke, K. ;
Kennedy, G. A. ;
George, A. ;
Fedele, P. L. ;
Gilbertson, M. ;
Tan, S. Y. ;
Ritchie, D. S. ;
Opat, S. S. ;
Prince, H. M. ;
Dickinson, M. ;
Burbury, K. ;
Wolf, M. ;
Januszewicz, E. H. ;
Tam, C. S. ;
Westerman, D. A. ;
Carney, D. A. ;
Harrison, S. J. ;
Seymour, J. F. .
BRITISH JOURNAL OF CANCER, 2014, 111 (06) :1072-1079
[4]   Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival [J].
Chen, Kai-Lin ;
Chen, Jie ;
Rao, Hui-Lan ;
Guo, Ying ;
Huang, Hui-Qiang ;
Zhang, Liang ;
Shao, Jian-Yong ;
Lin, Tong-Yu ;
Jiang, Wen-Qi ;
Zou, De-Hui ;
Hu, Li-Yang ;
Wirian, Michael Lucas ;
Cai, Qing-Qing .
CHINESE JOURNAL OF CANCER, 2015, 34
[5]   Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model [J].
Chihara, Dai ;
Oki, Yasuhiro ;
Matsuo, Keitaro ;
Onoda, Hiroshi ;
Taji, Hirofumi ;
Yamamoto, Kazuhito ;
Morishima, Yasuo .
LEUKEMIA & LYMPHOMA, 2011, 52 (12) :2270-2275
[6]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[7]   Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era [J].
Ferreri, Andres J. M. ;
Bruno-Ventre, Marta ;
Donadoni, Giovanni ;
Ponzoni, Maurilio ;
Citterio, Giovanni ;
Foppoli, Marco ;
Vignati, Alessandro ;
Scarfo, Lydia ;
Sassone, Marianna ;
Govi, Silvia ;
Caligaris-Cappio, Federico .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (05) :654-662
[8]   Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab [J].
Feugier, P ;
Virion, JM ;
Tilly, H ;
Haioun, C ;
Marit, G ;
Macro, M ;
Bordessoule, D ;
Recher, C ;
Blanc, M ;
Molina, T ;
Lederlin, P ;
Coiffier, B .
ANNALS OF ONCOLOGY, 2004, 15 (01) :129-133
[9]   Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte [J].
Feugier, P ;
Van Hoof, A ;
Sebban, C ;
Solal-Celigny, P ;
Bouabdallah, R ;
Fermé, C ;
Christian, B ;
Lepage, E ;
Tilly, H ;
Morschhauser, F ;
Gaulard, P ;
Salles, G ;
Bosly, A ;
Gisselbrecht, C ;
Reyes, F ;
Coiffier, B .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4117-4126
[10]   Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era [J].
Fletcher, Christopher D. ;
Kahl, Brad S. .
LEUKEMIA & LYMPHOMA, 2014, 55 (10) :2228-2240